BRIEF published on 06/17/2025 at 20:35, 10 months 20 days ago L'Assemblée Générale de GENFIT approuve les résolutions du Conseil d'Administration Resolutions Produits Biopharmaceutiques Assemblée Générale Des Actionnaires GENFIT Maladies Du Foie
BRIEF published on 06/17/2025 at 20:35, 10 months 20 days ago GENFIT's Shareholder Meeting Approves Board's Resolutions Biopharmaceuticals Resolutions Liver Diseases Shareholders Meeting GENFIT
PRESS RELEASE published on 06/17/2025 at 20:30, 10 months 20 days ago GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025 GENFIT annonce les résultats de son Assemblée Générale Mixte du 17 juin 2025, approuvés avec un quorum de 27,21%, tout en dévoilant sa mission et activités dans le secteur biopharmaceutique Biopharmaceutique Assemblée Générale Mixte Maladies Rares GENFIT Foie
PRESS RELEASE published on 06/17/2025 at 20:30, 10 months 20 days ago GENFIT: June 17, 2025 Combined Shareholders Meeting Results GENFIT announces approval of all resolutions at June 17, 2025 Combined Shareholders Meeting. Exception: resolution n°28 rejected. Quorum: 27.21% Resolutions Approval Quorum Shareholders Meeting GENFIT
BRIEF published on 05/22/2025 at 22:15, 11 months 16 days ago GENFIT : Résultats financiers du premier trimestre 2025 Trésorerie Royalties GENFIT Iqirvo® Phase Clinique
BRIEF published on 05/22/2025 at 22:15, 11 months 16 days ago GENFIT: First Quarter 2025 Financial Results Treasury Royalties GENFIT Iqirvo® Clinical Phase
PRESS RELEASE published on 05/22/2025 at 22:10, 11 months 16 days ago GENFIT Reports First Quarter 2025 Financial Information GENFIT reports Q1 2025 financial information showing cash position growth and revenue increase. Details on Royalty Financing agreement, research efforts, and corporate governance update included Financial Information Revenue Cash Position GENFIT Q1 2025
PRESS RELEASE published on 05/22/2025 at 22:10, 11 months 16 days ago GENFIT : Information financière du premier trimestre 2025 GENFIT annonce sa position de trésorerie au 31 mars 2025 et son chiffre d’affaires pour le premier trimestre 2025. L'entreprise évolue dans le domaine des maladies rares du foie Chiffre D'affaires Trésorerie Maladies Rares GENFIT Foie
BRIEF published on 05/20/2025 at 22:15, 11 months 18 days ago GENFIT reçoit 26,5 millions d'euros suite à une étape clé en Italie Italie Cholangite Biliaire Primitive GENFIT Iqirvo® Versament D'étape
BRIEF published on 05/20/2025 at 22:15, 11 months 18 days ago GENFIT receives €26.5 million following a key milestone in Italy Italy Primary Biliary Cholangitis GENFIT Milestone Payment Iqirvo®
Published on 05/08/2026 at 01:50, 57 minutes ago Apex Critical Metals Announces Grant of Stock Options and RSUs
Published on 05/08/2026 at 00:45, 2 hours 2 minutes ago Route1 Announces First Quarter 2026 Financial Results Notification
Published on 05/08/2026 at 00:00, 2 hours 47 minutes ago Redwood AI Approved to Receive National Research Council of Canada Funding for its Q-SAFE Chemical Screening Project for Defence and Security Applications
Published on 05/07/2026 at 23:30, 3 hours 17 minutes ago Faraday Copper Reports First Quarter 2026 Financial Results
Published on 05/07/2026 at 23:15, 3 hours 32 minutes ago BULGOLD Adopts Semi-Annual Financial Reporting
Published on 05/07/2026 at 23:23, 3 hours 23 minutes ago H1 25/26: Challenging environment and significant changes in IT market // Revised forecast // Programme to boost competitiveness
Published on 05/07/2026 at 23:14, 3 hours 33 minutes ago EQS-Adhoc: All for One Group SE revises forecast for 2025/26 financial year // »Precision« programme to boost competitiveness approved
Published on 05/07/2026 at 22:05, 4 hours 42 minutes ago Univar Solutions Announces Leadership Evolution
Published on 05/07/2026 at 20:42, 6 hours 5 minutes ago RHÖN-KLINIKUM AG reports stable development in the first quarter of 2026
Published on 05/07/2026 at 18:46, 8 hours 1 minute ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/07/2026 at 19:15, 7 hours 32 minutes ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 7 hours 32 minutes ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 7 hours 41 minutes ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 7 hours 41 minutes ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 7 hours 47 minutes ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
